<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579553</url>
  </required_header>
  <id_info>
    <org_study_id>Progesterone75,643</org_study_id>
    <nct_id>NCT00579553</nct_id>
  </id_info>
  <brief_title>Comparing IM vs. Vaginal Progesterone for Pre-term Birth</brief_title>
  <official_title>Comparing Intramuscular Versus Vaginal Progesterone for Prevention of Preterm Birth.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial comparing weekly intramuscular injection of 17 alpha&#xD;
      hydroxylprogesterone caproate with daily vaginal progesterone in women with singleton&#xD;
      pregnancies and history of prior spontaneous preterm birth in terms of maternal, fetal and&#xD;
      neonatal outcomes.&#xD;
&#xD;
      Our aim is to assess the effects on maternal, fetal and neonatal outcomes of antenatal&#xD;
      progesterone administered intramuscularly versus vaginally in women with singleton pregnancy&#xD;
      and a history of prior preterm birth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended as a randomized controlled trial. Women with singleton pregnancies&#xD;
      between 16 and 20 weeks 6 day will be randomized to one of two treatment groups.&#xD;
&#xD;
      Those randomized to weekly intramuscular progesterone will receive 250 mg of 17 alpha&#xD;
      hydroxyprogesterone caproate every week in the clinic between randomization and delivery for&#xD;
      those delivery preterm or 36 weeks 6 days.&#xD;
&#xD;
      While those randomized to vaginal progesterone will receive 100 mg vaginal progesterone daily&#xD;
      at home. Vaginal progesterone to last between clinic visits will be provided to subject.&#xD;
      Those women in the vaginal progesterone group will also be informed on how to obtain&#xD;
      additional medication in case of missed clinic appointment. Treatment will be continued until&#xD;
      36 weeks 6 days or as dictated by date of preterm delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm Birth</measure>
    <time_frame>From 16-20 weeks gestation through preterm delivery</time_frame>
    <description>Delivery before 37 weeks gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth</measure>
    <time_frame>From 16-20 weeks gestation through preterm delivery</time_frame>
    <description>Delivery below 34 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Delivery</measure>
    <time_frame>From 16-20 weeks gestation through preterm delivery</time_frame>
    <description>Mean gestational age at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Neonatal Birth Weight</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Infant, Premature</condition>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Intramuscular Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular Progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaginal Progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Progesterone</intervention_name>
    <description>Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
    <arm_group_label>Intramuscular Progesterone</arm_group_label>
    <other_name>17 alpha hydroxyprogesterone caproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Progesterone</intervention_name>
    <description>Vaginal Progesterone: 100 mg vaginal suppository daily</description>
    <arm_group_label>Vaginal Progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancies&#xD;
&#xD;
          -  History of spontaneous preterm brith (between 20 weeks and 36 weeks 6 days)&#xD;
&#xD;
          -  Gestational age between 16 weeks 0 days and 20 weeks 6 days.&#xD;
&#xD;
          -  Signed consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple Gestation&#xD;
&#xD;
          -  Prior elective fetal reduction or planned termination&#xD;
&#xD;
          -  Known spontaneous reduction to singleton&#xD;
&#xD;
          -  Major fetal anomaly or known fetal chromosomal abnormalities&#xD;
&#xD;
          -  Progesteone used this pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Elimian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre Term</keyword>
  <keyword>Pre Term Birth</keyword>
  <keyword>Premature Birth</keyword>
  <keyword>Premature baby</keyword>
  <keyword>High risk pregnancy</keyword>
  <keyword>Progesterone</keyword>
  <keyword>IM Progesterone</keyword>
  <keyword>Vaginal Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>17 alpha-Hydroxyprogesterone Caproate</mesh_term>
    <mesh_term>11-hydroxyprogesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intramuscular Progesterone</title>
          <description>Intramuscular Progesterone&#xD;
Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
        </group>
        <group group_id="P2">
          <title>Vaginal Progesterone</title>
          <description>Vaginal Progesterone&#xD;
Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intramuscular Progesterone</title>
          <description>Intramuscular Progesterone&#xD;
Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
        </group>
        <group group_id="B2">
          <title>Vaginal Progesterone</title>
          <description>Vaginal Progesterone&#xD;
Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" spread="4.3"/>
                    <measurement group_id="B2" value="26.8" spread="4.7"/>
                    <measurement group_id="B3" value="26.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Educational Level</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>College</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High School</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Less than high school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Tobacco use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No tobacco use</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preterm Birth</title>
        <description>Delivery before 37 weeks gestation.</description>
        <time_frame>From 16-20 weeks gestation through preterm delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Progesterone</title>
            <description>Intramuscular Progesterone&#xD;
Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Progesterone</title>
            <description>Vaginal Progesterone&#xD;
Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Birth</title>
          <description>Delivery before 37 weeks gestation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Birth</title>
        <description>Delivery below 34 weeks gestation</description>
        <time_frame>From 16-20 weeks gestation through preterm delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Progesterone</title>
            <description>Intramuscular Progesterone&#xD;
Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Progesterone</title>
            <description>Vaginal Progesterone&#xD;
Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Birth</title>
          <description>Delivery below 34 weeks gestation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delivery less than 34 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delivery less than 28 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Delivery</title>
        <description>Mean gestational age at delivery</description>
        <time_frame>From 16-20 weeks gestation through preterm delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Progesterone</title>
            <description>Intramuscular Progesterone&#xD;
Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Progesterone</title>
            <description>Vaginal Progesterone&#xD;
Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at Delivery</title>
          <description>Mean gestational age at delivery</description>
          <units>Weeks gestation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="4.7"/>
                    <measurement group_id="O2" value="36.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Neonatal Birth Weight</title>
        <time_frame>At delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Progesterone</title>
            <description>Intramuscular Progesterone&#xD;
Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Progesterone</title>
            <description>Vaginal Progesterone&#xD;
Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Neonatal Birth Weight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2680.6" spread="840"/>
                    <measurement group_id="O2" value="2771.6" spread="1131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intramuscular Progesterone</title>
          <description>Intramuscular Progesterone&#xD;
Intramuscular Progesterone: Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P</description>
        </group>
        <group group_id="E2">
          <title>Vaginal Progesterone</title>
          <description>Vaginal Progesterone&#xD;
Vaginal Progesterone: Vaginal Progesterone: 100 mg vaginal suppository daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Elimian, MD</name_or_title>
      <organization>University of Oklahoma Health Science Center</organization>
      <phone>19146465194</phone>
      <email>aelimian@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

